As drug developers face mounting pressure to accelerate discovery timelines without sacrificing quality, QLNS-CHO offers a compelling solution.

In addition to cell line development, CHO Plus partnered to scale up Avid Bioservices' mAb production to meet industrial scale requirements.

A CHO cell line secreting human IgG4κ antibodies was mixed with Cyto-Cellect ® reagents (Donor conjugated with AF488 [Green], Acceptor with AF594 [Orange]) and a viability dye conjugated to ...

IPOs worth Rs 2.58 lakh crore are currently lined up, including Rs 1.15 lakh crore in offers that have already received SEBI’s approval, and another Rs 1.43 lakh crore awaiting the green light.